03008-5. PMID: 39054336; PMCID: PMC11272929. DEVELOPMENT OF ESKETAMINE. AN ACADEMIC -INDUSTRY DREAM COLLABORATION

The development of esketamine represents a remarkable example of how collaboration between academia and industry can accelerate the translation of basic science into transformative clinical innovation. The story began Yale University and at the National Institutes of Health (NIH), where pioneering academic research first revealed the rapid antidepressant effects of ketamine, uncovering a completely new mechanism of action distinct from traditional monoaminergic pathways. Building on these foundational discoveries, industry efforts focused on translating this knowledge into a safe, effective, and regulatory-approvable therapy for patients with treatment-resistant depression. What made this journey particularly unique was that ketamine, unlike most investigational compounds, was already available for clinical use during its clinical development. This allowed clinicians and researchers to explore its therapeutic potential in real-world settings even as formal trials of esketamine were underway. Consequently, the development process raised atypical scientific and clinical questions—such as optimal dosing frequency and longterm safety—that could not be addressed solely through conventional pharmacokinetic principles like half-life. Academic investigators played a critical role in shaping these discussions by generating real-world data, exploring mechanisms of action, and advancing understanding of ketamine’s enantiomers. In parallel, industry provided the infrastructure for large-scale clinical trials, regulatory engagement, and drug formulation. Together, these complementary efforts established a dynamic feedback loop—academic findings informed industry development, and industry-generated data refined clinical practice. The outcome of this collaboration was the successful approval of the first antidepressant with a novel mechanism of action in over half a century. Beyond its scientific impact, the development of esketamine highlights how open communication, shared curiosity, and joint problem-solving across sectors can overcome traditional barriers in drug discovery. This partnership between academic innovation and industrial development not only transformed the treatment landscape for depression but also set a new precedent for how future neuropsychiatric therapeutics might be discovered and brought to patients.

References

Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016;173(8):816-826 Singh JB, Fedgchin M, Daly EJ, Drevets WC. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. Adv Pharmacol. 2020;89:237259.